First & Only DNA testing service with Multiple FDA clearances
23andMe pioneered access to genetic information. We weren’t just the first to do it, we are the only direct-to-consumer DNA testing service with multiple FDA authorizations for genetic health reports.
Our services
23andMe+ Premium™
Advanced Ancestry + Health
Membership fueled by discovery, sharpened by time. Provides 100+ genetic insights and action tools.
FSA & HSA Eligible
23andMe+ Total Health™
Ultimate Health + Advanced Ancestry
Our most advanced health kit. Includes next-generation DNA analyses and blood testing to provide cutting-edge longevity insights and guidance toward a healthier you.
FSA & HSA Eligible
* 23andMe+ Premium renews at $69 per year. Cancel anytime.23andMe+ Total Health renews at $199 per year. Cancel anytime.
Connect the dots between past, present, and future you.
Best in class genotyping experience combines the most comprehensive ancestry breakdown with 100+ health reports and insights. Plus ongoing information based on your DNA as the science becomes available.
23andMe+ Total Health
Total Health is a next gen longevity platform built with the tools to not only help you live more years, but to live more healthy years. Discover a new take on growing older.
Learn more about Total HealthPrivacy by design
There is no advanced science that comes before your protection. Read more about our enhanced measures designed to keep your data safe, in any scenario.
Learn moreThings you might be wondering:
23andMe has rigorous standards that ensure high-quality results. Our team of scientists and medical experts use a robust process to develop genetic reports for our customers. Here are specific examples:
- With one of the largest reference datasets in the world, 23andMe provides customers with one of the most detailed and accurate ancestry breakdowns on the market. Our algorithms make ancestry estimates based on probabilities and they’re generally very accurate, but your results are not set in stone. We are always trying to improve and refine these estimates.
After you provide a saliva sample, 23andMe uses genotyping to analyze your DNA. This means we look at specific locations in your genome that are known to differ between people. We then turn those results into personalized genetic reports on everything from ancestry composition to traits to genetic health risks. Note that genotyping is different from DNA sequencing, which looks at every letter in a particular stretch of DNA.
Most adults who are able to provide saliva samples can use the 23andMe kit. However there are some considerations that can complicate the DNA accuracy. Check out our Terms of Service for more info on those cases.
To begin, visit www.23andme.com/start. Once you have successfully registered your DNA testing kit, provided a saliva sample and put the kit in the mail, you can use the return tracking link available on your profile homepage to track your kit's progress to the lab. Once your sample reaches the lab, it is typically processed within a few weeks, with results then delivered to your secure online account.
We encourage customers to provide their sample before the "Collect saliva by" date on the side of the collection tube. If your sample collection kit is lost or damaged, or if it has expired, please contact customer care to assist you with getting a replacement kit.
There are many benefits of DNA testing, including finding relatives and receiving personalized insights into your insights into your health and ancestry. 23andMe+ Premium Service offers 190+ DNA reports that do just that. In addition to taking greater control of your own health and digging deeper into your ancestry, you can also opt in to participate in research that could help fuel scientific discoveries that benefit the larger community.
We're also committed to providing you with a safe place where you can learn about your DNA knowing your privacy is protected. 23andMe has sold 12+ million kits, and with each and every one of those, privacy has been our number one priority. You may learn more about our commitment to privacy hereon our privacy page.
Stay in the know.
Keep up-to-date with new discoveries and exclusive promotions on our DNA testing kits and services.
**The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. This report is for over-the-counter use by adults over the age of 18, and provides genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/
***23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/
triangleExome Sequencing and blood testing services are available to eligible customers upon completion of the intake questionnaire that must be reviewed, approved and ordered by a third-party clinician. Exome Sequencing is analyzed by a CLIA- and CAP-accredited laboratory. Blood testing is completed by Quest Diagnostics. All telehealth services are provided in accordance with the Telehealth Terms and Consent to Telehealth.
◆Based on purchase price of $199. Check with your FSA/HSA administrator or your tax professional for confirmation on the specific requirements for individual eligibility and reimbursement, including usage, procedures and qualifications.